Partners separately announce strong Phase I data and Phase III plans for GFH375 (VS-7375), an oral KRAS G12D (ON/OFF) inhibitor, for colorectal cancer in and outside of China.
Partners separately announce strong Phase I data and Phase III plans for GFH375 (VS-7375), an oral KRAS G12D (ON/OFF) inhibitor, for colorectal cancer in and outside of China.